Literature DB >> 24504853

How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.

H G M van Haalen1, J L Severens, A Tran-Duy, A Boonen.   

Abstract

OBJECTIVE: In the current study, we propose an approach for selection of a model that is transferable to a specific decision-making context (in this case, the Netherlands), using the case of rheumatoid arthritis (RA). The objectives of this study were (a) to perform a systematic literature review to identify existing health economic evaluation models for economic evaluation of disease-modifying antirheumatic drugs (DMARDs) in RA; and (b) to test the appropriateness of a stepwise model-selection process.
METHODS: First, we searched Medline and Embase to identify relevant studies in the English language, published between 1 January 2002 and 31 August 2012. From the included studies, all unique models were identified. Second, we applied a multi-step approach to model selection. Models that did not meet all minimal methodological and structural requirements based on the Outcome Measures in Rheumatology (OMERACT) criteria were excluded. Next, models were assessed on the basis of their fit when transferred to the Dutch health care setting. The criteria for model fit were transferability factors, as published by Welte et al., after exclusion of those that were deemed transferable by simple adaptation. Finally, the remaining models underwent a general quality check using the Philips checklist. Models showing good fit and high quality were considered to be transferable to the Dutch health care setting, using simple adaptation.
RESULTS: The systematic literature search identified 498 articles, which included 33 unique health economic evaluation models. Only six models passed the minimal methodological and structural requirements. Two of these models had an imperfect transferability fit to the Dutch health care setting, according to the Welte method. The remaining four models were, according to the Philips method, of good quality and were expected to be transferable by a simple adaptation.
CONCLUSION: This study introduces a stepwise approach for selecting health economic evaluation models that are transferable by a simple adaptation. The approach seems feasible and can be applied in various therapeutic areas, provided that the minimal methodological and structural requirements are defined accordingly. Availability of health economic evaluation models coupled with structured model selection could improve the efficiency, quality and comparability of health economic research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24504853     DOI: 10.1007/s40273-014-0139-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  66 in total

1.  Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Authors:  Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; Carter Thorne; Ross Maclean; Danielle Dupont
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

2.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

3.  Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case.

Authors:  Andreas Maetzel; Peter Tugwell; Maarten Boers; Francis Guillemin; Doug Coyle; Mike Drummond; John B Wong; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2003-04       Impact factor: 4.666

4.  Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug strategies in patients with early rheumatoid arthritis.

Authors:  Jonathan C Tosh; Allan J Wailoo; David L Scott; Chris M Deighton
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

5.  Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective.

Authors:  Lydia G Schipper; Wietske Kievit; Alfons A den Broeder; Mart A van der Laar; Eddy M M Adang; Jaap Fransen; Piet L C M van Riel
Journal:  Rheumatology (Oxford)       Date:  2011-03-02       Impact factor: 7.580

6.  Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.

Authors:  G Kobelt; P Lindgren; A Singh; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

7.  Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

Authors:  N J Bansback; A Brennan; O Ghatnekar
Journal:  Ann Rheum Dis       Date:  2004-11-18       Impact factor: 19.103

8.  Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.

Authors:  Yong Yuan; Digisha Trivedi; Ross Maclean; Lisa Rosenblatt
Journal:  J Med Econ       Date:  2010-03       Impact factor: 2.448

9.  Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.

Authors:  M Vera-Llonch; E Massarotti; F Wolfe; N Shadick; R Westhovens; O Sofrygin; R Maclean; Y Yuan; G Oster
Journal:  Rheumatology (Oxford)       Date:  2008-04       Impact factor: 7.580

10.  Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

Authors:  Gisela Kobelt; Linus Jönsson; Peter Lindgren; Adam Young; Kerstin Eberhardt
Journal:  Arthritis Rheum       Date:  2002-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.